Insulin Correction Dose Calculator
Calculate the supplemental (correction) insulin dose needed to bring an elevated blood glucose back to target, using the patient’s individual insulin sensitivity factor (ISF). Includes an ISF estimator based on the 1800 and 1500 rules.
Calculate Correction Insulin Dose
Enter the patient’s current blood glucose, target glucose, and known insulin sensitivity factor (ISF) to calculate the correction dose. If the ISF is unknown, use the ISF Estimator below to derive it from the total daily dose (TDD).
This calculator provides an estimated correction dose. Insulin dosing must account for active insulin on board (IOB), recent meals, planned activity, intercurrent illness, and the clinical setting. Correction doses should be reviewed and adjusted by a qualified clinician. Inappropriate correction dosing is a leading cause of iatrogenic hypoglycaemia.
Estimate Insulin Sensitivity Factor
If the patient’s ISF is not known, it can be estimated from the total daily dose (TDD) of insulin. The 1800 Rule applies to rapid-acting analogues and the 1500 Rule applies to regular insulin.
Understanding Insulin Sensitivity Factor & Correction Dosing
The insulin sensitivity factor (ISF), also called the correction factor, quantifies how much one unit of insulin is expected to lower blood glucose. It is the cornerstone of correction dosing — the practice of giving supplemental rapid-acting or regular insulin to bring an elevated glucose back toward the target range.
The correction dose formula is a simple ratio: the difference between the current glucose and the target glucose, divided by the ISF. The result tells the clinician how many units of insulin are needed to close the gap. This calculation underpins insulin sliding scales, insulin pump correction boluses, and dose-adjustment protocols in both inpatient and outpatient settings.
Correction Dose Formula
Dose (units) = (Current BG − Target BG) ÷ ISF
Example: Current BG 280 mg/dL, Target 120 mg/dL, ISF 40 mg/dL per unit → (280 − 120) ÷ 40 = 4 units
ISF Estimation Rules
ISF = 1800 ÷ TDD (rapid-acting)
ISF = 1500 ÷ TDD (regular insulin)
Example: TDD 45 units, rapid-acting → 1800 ÷ 45 = ISF ≈ 40 mg/dL per unit
The ISF is a starting estimate, not a final prescription. The 1800 and 1500 rules provide a population-derived approximation. Individual patients may be significantly more or less insulin-sensitive due to factors including body composition, insulin resistance, physical activity level, intercurrent illness, corticosteroid use, and time of day. ISF should be validated and adjusted based on observed glucose responses over 2–3 days.
Correction Dose Interpretation & Glucose Targets
The calculated correction dose should be interpreted in the context of the patient’s clinical setting, diabetes type, and individualised glycaemic targets. The following table summarises commonly used glucose targets and the corresponding clinical context.
| Clinical Setting | Target BG (mg/dL) | Target BG (mmol/L) | Notes |
|---|---|---|---|
| General inpatient (non-ICU) | 140–180 | 7.8–10.0 | ADA/AACE consensus; avoid < 70 |
| ICU / critically ill | 140–180 | 7.8–10.0 | Tight control (< 110) shown to increase mortality (NICE-SUGAR) |
| Outpatient — most adults | 80–130 (pre-meal) | 4.4–7.2 | ADA standard target for self-management |
| Outpatient — elderly / high risk | 100–180 | 5.6–10.0 | Less stringent to avoid hypoglycaemia |
| Pregnancy (pre-existing DM) | 60–95 (fasting), < 140 (1h post) | 3.3–5.3 / < 7.8 | Tighter targets; individualised |
| Paediatric — Type 1 | 70–150 | 3.9–8.3 | Age-dependent; CGM-guided preferred |
Correction insulin alone — without scheduled basal and prandial coverage — is reactive rather than preventive. The “sliding scale only” approach is associated with greater glycaemic variability and worse outcomes compared to basal-bolus regimens. Correction doses should supplement a basal-bolus regimen, not replace it. The landmark RABBIT 2 trial demonstrated that basal-bolus therapy achieves better glycaemic control than sliding scale alone in hospitalised patients with type 2 diabetes.
Typical ISF Ranges by Clinical Context
| Patient Profile | Typical TDD (units) | ISF — 1800 Rule (mg/dL/unit) | ISF — mmol/L/unit |
|---|---|---|---|
| Type 1 — lean, insulin-sensitive | 20–30 | 60–90 | 3.3–5.0 |
| Type 1 — average | 30–50 | 36–60 | 2.0–3.3 |
| Type 2 — moderate resistance | 40–80 | 23–45 | 1.3–2.5 |
| Type 2 — significant resistance | 80–150+ | 12–23 | 0.7–1.3 |
| Paediatric (prepubertal) | 10–20 | 90–180 | 5.0–10.0 |
Factors Affecting Insulin Sensitivity & Correction Dosing
Insulin sensitivity is dynamic and influenced by numerous physiological and pathological factors. A correction dose that is appropriate at one time may be insufficient or excessive under different circumstances. Clinicians must account for these variables when prescribing correction doses.
Insulin stacking is the most common cause of iatrogenic hypoglycaemia from correction dosing. It occurs when a new correction dose is administered before the previous dose has completed its action. Rapid-acting insulin analogues (lispro, aspart, glulisine) have a duration of action of approximately 3–5 hours, with peak effect at 1–2 hours. Regular insulin acts for 6–8 hours with peak at 2–4 hours.
If a patient received 4 units of rapid-acting insulin 2 hours ago, a substantial portion of that dose is still active. Administering another full correction dose at the 2-hour mark would effectively double the insulin exposure, risking severe hypoglycaemia. Insulin pumps automatically account for IOB when suggesting correction boluses. When calculating manually, clinicians should subtract the estimated remaining active insulin from the calculated correction dose. A common rule of thumb: approximately 20% of a rapid-acting dose is consumed per hour after the first hour.
- Wait at least 3–4 hours between rapid-acting correction doses
- Account for any recent prandial (meal) bolus still in effect
- In hospital settings, nursing protocols should flag corrections given within 4 hours of the last dose
Acute illness significantly increases insulin resistance through the counter-regulatory hormone response — cortisol, glucagon, catecholamines, and growth hormone all promote hepatic gluconeogenesis and impair peripheral glucose uptake. Patients with sepsis, post-surgical stress, acute myocardial infarction, or severe infection commonly require 50–100% more insulin than their usual doses.
In the inpatient setting, correction factor protocols should be reviewed daily and adjusted for the patient’s clinical trajectory. A patient who was insulin-sensitive on admission may become profoundly resistant during an ICU stay and then return to baseline sensitivity during recovery. Static sliding scales fail to account for this dynamic reality, which is why individualised correction factors — recalculated from the observed TDD — are preferred.
- Fever alone can increase insulin requirements by 10–20%
- Corticosteroid therapy (a very common inpatient scenario) dramatically increases resistance, particularly in the afternoon/evening for morning-dosed steroids
- Recovery phase: taper correction aggressively as illness resolves to avoid hypoglycaemia
Physical activity enhances insulin sensitivity through both insulin-dependent and insulin-independent pathways. During exercise, skeletal muscle contraction activates GLUT4 translocation independently of insulin signalling, increasing glucose uptake. This enhanced sensitivity persists for 24–48 hours after exercise, meaning correction doses given in the post-exercise period carry a higher risk of hypoglycaemia.
In the outpatient setting, patients who exercise regularly often need different ISF values for active versus sedentary days. A Type 1 patient with an ISF of 50 mg/dL/unit on rest days may effectively be 70–80 mg/dL/unit after a vigorous training session. Insulin pump users can program different correction factors for active periods. For hospitalised patients, even mild mobilisation (e.g., walking in the corridor, physiotherapy sessions) can affect glucose levels — this is particularly relevant when patients transition from bed rest to ambulation.
Chronic kidney disease (CKD) has a complex relationship with insulin metabolism. The kidneys are responsible for approximately 30–80% of insulin clearance — as renal function declines, exogenous insulin clearance is reduced, effectively increasing insulin sensitivity and prolonging its duration of action. Patients with CKD stages 4–5 (eGFR < 30) often require 25–50% lower insulin doses compared to their requirements at earlier CKD stages, and their ISF may need to be significantly larger (i.e., each unit has a greater glucose-lowering effect).
Hepatic impairment also reduces insulin clearance (the liver clears approximately 50% of portal insulin on first pass) and impairs glycogen storage, increasing vulnerability to both hyperglycaemia and hypoglycaemia. In cirrhotic patients, insulin dosing must be conservative with frequent monitoring. Additionally, uraemia itself can cause insulin resistance at the tissue level, creating a paradoxical situation where patients may need less total insulin but have an unpredictable response to individual doses.
Insulin sensitivity follows a circadian rhythm. Most individuals are more insulin-resistant in the early morning hours (approximately 4:00–8:00 AM) due to the dawn phenomenon — a physiological surge in growth hormone, cortisol, and hepatic glucose output. This means that a correction dose given at 6:00 AM may be less effective (unit-for-unit) than the same dose given at noon or in the evening.
Insulin pump users can program time-variable correction factors to account for this pattern — for example, an ISF of 40 mg/dL/unit from midnight to 10:00 AM and 50 mg/dL/unit from 10:00 AM to midnight. For patients on injection therapy, clinicians should be aware that morning fasting hyperglycaemia may require a larger correction dose than the same elevation later in the day, and that evening corrections should be more conservative to avoid nocturnal hypoglycaemia.
Before administering a correction dose, always ask: (1) When was the last insulin dose, and how much is still on board? (2) Has the patient eaten recently, and is more carbohydrate absorption expected? (3) Is the patient more or less insulin-sensitive than usual today (illness, steroids, exercise, renal function)? (4) What is the risk of hypoglycaemia in this individual patient?
Special Populations
Correction dose calculations require additional caution and modified parameters in several patient populations where insulin pharmacokinetics, sensitivity, or the risk of hypoglycaemia differ from the general adult population.
The 1800/1500 rules were derived predominantly from adult populations with Type 1 diabetes. They serve as a starting point in all populations, but should be validated against observed glucose responses within 2–3 days. In insulin-naïve Type 2 patients being started on correction-dose insulin for the first time (e.g., hospitalisation), starting with a conservative ISF (higher number, e.g., 50–70 mg/dL/unit) and titrating based on response is safer than relying on a TDD that has not yet been established.
Common Pitfalls & Limitations
Administering a new correction dose before the previous one has completed its action is the single most common cause of iatrogenic hypoglycaemia related to correction dosing. This typically occurs when a patient’s glucose is rechecked 1–2 hours after a correction dose, found still to be elevated, and another full correction dose is given. Because rapid-acting insulin has a duration of action of 3–5 hours, the first dose may still be exerting significant glucose-lowering effect at the 2-hour mark.
How to avoid: Enforce a minimum interval of 3–4 hours between correction doses. In hospital settings, use nursing protocols that flag recent insulin administration. Insulin pumps calculate IOB automatically — for manual dosing, subtract an estimated IOB from the calculated correction. If a patient’s glucose remains elevated 4 hours after a correction, reassess the ISF (it may be too high) and review whether basal insulin is adequate.
A correction-only (sliding scale) approach treats hyperglycaemia reactively rather than preventing it proactively. Without scheduled basal insulin, patients experience repeated cycles of hyperglycaemia followed by correction-induced troughs, resulting in high glycaemic variability. The RABBIT 2 trial and subsequent studies have demonstrated that basal-bolus regimens achieve better glycaemic control, fewer complications, and shorter hospital stays than sliding scale insulin alone in Type 2 diabetes inpatients.
How to avoid: Always pair correction doses with a basal insulin regimen (and prandial insulin if the patient is eating). Use correction doses as a supplement to the scheduled regimen, not as the sole insulin therapy. If a patient consistently requires more than 2 correction doses per day, the basal and/or prandial doses are inadequate and should be increased.
Treating the ISF as a fixed number ignores the dynamic nature of insulin sensitivity. A patient who is started on dexamethasone for cerebral oedema may see their insulin requirements double or triple within 24 hours. Conversely, a septic patient whose antibiotics are working may become dramatically more insulin-sensitive as the infection clears. If the ISF is not recalculated to reflect these changes, the correction doses will be persistently too small (resulting in uncorrected hyperglycaemia) or too large (causing hypoglycaemia).
How to avoid: Recalculate the ISF from the previous day’s observed TDD at least once daily in hospitalised patients. Be proactive about adjusting when new medications are started (especially corticosteroids, vasopressors, or octreotide), when nutritional intake changes, or when the clinical trajectory shifts. Document the rationale for ISF changes to maintain continuity across shifts.
The target blood glucose used in the correction formula directly affects the calculated dose. Using a target of 100 mg/dL in an elderly patient on a general medical ward produces a much larger correction dose than a target of 150 mg/dL — and places that patient at significantly greater risk of hypoglycaemia. The NICE-SUGAR trial demonstrated that targeting blood glucose of 81–108 mg/dL in ICU patients increased mortality compared to a target of ≤ 180 mg/dL.
How to avoid: Individualise targets. For most hospitalised patients, 140–180 mg/dL is appropriate. For outpatients, the ADA recommends 80–130 mg/dL pre-meal for most non-pregnant adults, but less stringent targets are appropriate for elderly patients, those with limited life expectancy, or those with hypoglycaemia unawareness. Always document the chosen target and ensure all members of the care team are using the same number.
An ISF of 50 in mg/dL is very different from an ISF of 50 in mmol/L. If a patient’s ISF is documented as 50 mg/dL per unit but a clinician misinterprets this as 50 mmol/L per unit (which would be extraordinarily insulin-sensitive), the resulting correction dose would be far too small. Conversely, using a mmol/L-based ISF (e.g., 2.8) in an mg/dL-based calculation would produce a massively excessive dose. This type of unit error has been reported in medication safety incident databases, particularly in international settings where both systems are used.
How to avoid: Always label the ISF with its unit. When the ISF is documented in clinical notes, specify “ISF = 50 mg/dL per unit” rather than just “ISF = 50.” Ensure that the glucose unit used for the current BG and target BG matches the ISF unit. Conversion: ISF (mmol/L) = ISF (mg/dL) ÷ 18.
Quick Reference Summary
ISF = 1800 ÷ TDD
ISF = 1500 ÷ TDD
Between Correction Doses
mg/dL (ADA/AACE)
| Decision Point | Key Principle |
|---|---|
| ISF not known | Use 1800 ÷ TDD (rapid-acting) or 1500 ÷ TDD (regular); validate in 2–3 days |
| Correction dose calculated | Subtract active insulin on board; round down if hypoglycaemia risk is high |
| BG still high after correction | Wait 3–4 hours before recorrecting; reassess ISF if pattern persists |
| ≥ 2 corrections/day needed | Increase scheduled basal and/or prandial insulin — do not rely on corrections alone |
| Hypoglycaemia after correction | Increase ISF (larger number = less insulin per unit); reassess target |
| New steroids started | Anticipate 50–100% increase in insulin requirement; pre-adjust ISF |
The Golden Rule: A correction dose is only as safe as the clinician’s awareness of what else is happening — active insulin on board, recent or upcoming meals, planned activity, intercurrent illness, and the patient’s individual risk of hypoglycaemia. Calculate the number, then think before you inject.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract. 2008;14(9):1095-1101. DOI: 10.4158/EP.14.9.1095
- Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30(9):2181-2186. DOI: 10.2337/dc07-0295
- NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283-1297. DOI: 10.1056/NEJMoa0810625
- American Diabetes Association Professional Practice Committee. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S295-S306. DOI: 10.2337/dc24-S016
- Walsh J, Roberts R, Bailey T. Guidelines for optimal bolus calculator settings in adults. J Diabetes Sci Technol. 2011;5(1):129-135. DOI: 10.1177/193229681100500118
- Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16-38. DOI: 10.1210/jc.2011-2098
- Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119-1131. DOI: 10.2337/dc09-9029
- Rabasa-Lhoret R, Garon J, Langelier H, Poisson D, Chiasson JL. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen. Diabetes Care. 1999;22(5):667-673. DOI: 10.2337/diacare.22.5.667